Search results
Lianhua Qingwen (simplified Chinese: 连花清瘟; traditional Chinese: 連花清瘟; lit. 'medicine using Forsythia suspensa and Lonicera japonica to clear illness', [1] LHQW) is a traditional Chinese medicine (TCM) formulation used for the treatment of influenza. [2]
Apr 19, 2022 · A clinical trial is under way to assess how Lianhua Qingwen capsules, a traditional Chinese medicine, may help speed up symptom recovery and negative ART test result in fully vaccinated adults with mild COVID-19. The study, initiated by the Singapore Chung Hwa Medical Institution, aims to provide evidence for TCM treatment of mild COVID-19 cases.
Nov 28, 2023 · Lianhuaqingwen (LHQW) capsules are traditional Chinese medicine formulae that inhibit SARS-CoV-2 replication and reduce inflammation. This study evaluated the efficacy and safety of LHQW capsules in adults with mild-to-moderate COVID-19 in four countries.
May 5, 2023 · Lianhua Qingwen (LHQW) is a new Chinese patent medicine for the treatment of cold and flu approved by the China’s National Medical Products Administration (NMPA).
May 16, 2020 · Lianhuaqingwen (LH) capsule, a repurposed marketed Chinese herb product, has been proven effective for influenza. Purpose. To determine the safety and efficacy of LH capsule in patients with Covid-19. Methods. We did a prospective multicenter open-label randomized controlled trial on LH capsule in confirmed cases with Covid-19.
Jun 3, 2022 · Lianhua Qingwen (LQ), a manufactured product composed of more than a dozen Chinese herbal medicines, has been shown to significantly inhibit SARS-CoV-2 replication, change virus morphology, and confer anti-inflammatory activity in vitro (Runfeng et al., 2020).
Lianhua Qingwen exerts anti-liver cancer effects and synergistic efficacy with sorafenib through PI3K/AKT pathway: Integrating network pharmacology, molecular docking, and experimental validation. Jin-rui Wei Xuqi Zhao Fuli Long Kunpeng Tian Lichuan Wu
